Rodman & Renshaw analyst Seema Sheoran initiated coverage of Camp4 Therapeutics (CAMP) with a Buy rating and $7 price target implying 55% upside. Camp4 is developing antisense oligonucleotides that target regulatory RNAs, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP: